Plant-Based = Higher Cost, Lower Quality. Be Sure To Tell Your Barista

Mar 15, 2022

Vegan activists like to hand-wring from time to time about surcharges to add their favorite plant-based beverage to their coffee drinks, citing all sorts of reasons behind the alleged injustice. Here’s a simpler explanation: Plant-based additives cost more because … they cost more.

Higher costs and lower quality are hallmarks of the “innovation” behind the proliferation of non-dairy products that trade on dairy terms in an attempt to win consumer favor. The lower nutritional content of plant-based beverages is well-established, with some almond brands having one-eighth the protein of dairy and none of them having the unique blend of 13 essential nutrients that set dairy apart. But here’s a quick refresher on the cost side of the equation:

cost of a gallon of milk

This is year-end data of the cost of a gallon of milk (all varieties) compared to alternatives, year-end 2021. Now you can see why marketers are so enthusiastic about selling highly processed oat water.

Here’s a comparison for yogurt

Here’s a comparison for yogurt. Not a surprise, when you look at the ingredients label of a pint of yogurt versus a plant-based alternative.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.